Results 121 to 130 of about 327,068 (394)

Uncertainty Quantification for Eosinophil Segmentation [PDF]

arXiv, 2023
Eosinophilic Esophagitis (EoE) is an allergic condition increasing in prevalence. To diagnose EoE, pathologists must find 15 or more eosinophils within a single high-power field (400X magnification). Determining whether or not a patient has EoE can be an arduous process and any medical imaging approaches used to assist diagnosis must consider both ...
arxiv  

Cholesterol-sensing liver X receptors stimulate Th2-driven allergic eosinophilic asthma in mice [PDF]

, 2016
Introduction: Liver X receptors (LXRs) are nuclear receptors that function as cholesterol sensors and regulate cholesterol homeostasis. High cholesterol has been recognized as a risk factor in asthma; however, the mechanism of this linkage is not known.
De Beuckelaer, Ans, Grooten, Johan, Gustafsson, Jan-Ake, Lambrecht, Bart, Naessens, Thomas, Smet, Muriel, Steffensen, Knut R, Van Hoecke, Lien, Vander Beken, Seppe, Vergote, Karl, Willart, Monique   +10 more
core   +1 more source

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Journal of Asthma and Allergy, 2021
Purpose Treatment of severe eosinophilic asthma (SEA) has been revolutionized by the development of monoclonal antibodies targeting underlying immunological pathways of eosinophilic asthma.
Moritz Z. Kayser, N. Drick, K. Milger, J. Fuge, N. Kneidinger, S. Korn, R. Buhl, J. Behr, T. Welte, H. Suhling   +9 more
semanticscholar   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma

Respiratory Research, 2023
Background Severe asthma is associated with substantial mortality and has unmet therapeutic need. A subset of severe asthma is characterized by neutrophilic airway inflammation.
Chenli Chang, Gongqi Chen, Wenliang Wu, Dian Chen, Shengchong Chen, Jiali Gao, Yuchen Feng, Guohua Zhen   +7 more
doaj   +1 more source

Nasal histamine responses in nonallergic rhinitis with eosinophilic syndrome [PDF]

, 2015
Background: Nonallergic rhinitis with eosinophilic syndrome (NARES) is persistent, without atopy, but with ≥25% nasal eosinophilia. Hypereosinophilia seems to contribute to nasal mucosa dysfunction.
Ciofalo, Andrea, de Vincentiis, Marco, Fusconi, Massimo, Greco, Antonio, Magliulo, Giuseppe, Romeo, Raffaello, Soldo, Pietro, Zambetti, Giampietro   +7 more
core   +1 more source

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

European Respiratory Journal, 2020
Background Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation.
C. Taillé, P. Chanez, G. Devouassoux, A. Didier, C. Pison, G. Garcia, J. Charriot, S. Bouée, A. Gruber, C. Pribil, A. Bourdin, M. Humbert   +11 more
semanticscholar   +1 more source

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma [PDF]

Allergy, Asthma & Clinical Immunology, 2019
Adolescents (12-17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU and ≥ 12 years of age in other regions (including the ...
Steven W. Yancey, Hector G. Ortega, Oliver N. Keene, Eric S. Bradford   +3 more
openaire   +4 more sources

Night‐Time Chronotherapy with Methylprednisolone Prevents an Acute Rejection in Pediatric Patients with Liver Transplantation: A Randomized Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Concept of methylprednisolone chronotherapy to prevent acute rejections. While endogenous cortisol secretion rises in the early morning, the number of lymphocytes in the blood is higher at night, thus exhibiting an antiphase pattern to cortisol secretion. Therefore, compared with the daytime, the infiltration of lymphocytes into immune‐reactive tissues
Kentaro Ushijima, Yukihiro Sanada, Shinya Otomo, Keiko Ogaki, Taiichi Wakiya, Noriki Okada, Yuta Hirata, Yasuharu Onishi, Yasunaru Sakuma, Yukiyo Wada, Akio Fujimura, Koichi Mizuta   +11 more
wiley   +1 more source

Deep Learning-Based Open Source Toolkit for Eosinophil Detection in Pediatric Eosinophilic Esophagitis [PDF]

arXiv, 2023
Eosinophilic Esophagitis (EoE) is a chronic, immune/antigen-mediated esophageal disease, characterized by symptoms related to esophageal dysfunction and histological evidence of eosinophil-dominant inflammation. Owing to the intricate microscopic representation of EoE in imaging, current methodologies which depend on manual identification are not only ...
arxiv